- Company
- Yuhan’s Leclaza to receive ₩100B in milestone payment
- by Chon, Seung-Hyun Aug 7, 2025 06:06am
- With Yuhan Corp’s new anticancer drug Leclaza approved in China, the company announced that it will receive KRW 63 billion in technology fees. Added to the technology fees secured at the end of last year for the drug’s approval in Europe, over KRW 100 billion in additional milestone payments are expected to be paid to the company. As a result,
- Company
- 'Brintellix', stable position in antidepressant drugs mkt
- by Eo, Yun-Ho Aug 7, 2025 06:05am
- 'Brintellix' has established a stable presence in the antidepressant drugs market over the past 10 years. Its presence has not been disturbed by issues such as generic entries. According to industry sources, Lundbeck Korea's Brintellix (vortioxetine) has been growing in the market for antidepressant drugs for the past 10 years. In Q1 2012
- Company
- COVID-19 vaccines transitioned to NIP
- by Whang, byung-woo Aug 6, 2025 06:10am
- COVID-19 vaccines, which were previously contracted through a pre-purchase model with pharmaceutical companies, will transition to the National Immunization Program (NIP) system. The Korea Disease Control and Prevention Agency (KDCA) announced on August 5 that it has signed a procurement contract for the supply of vaccines for the 2025-202
- Company
- Imfinzi wins nod as pre- and post-operative adjuvant therapy
- by Whang, byung-woo Aug 6, 2025 06:10am
- AstraZeneca announced on August 4 that it has received approval for its Imfinzi (durvalumab) as pre- and post-operative adjuvant therapy for patients with muscle-invasive bladder cancer from the Ministry of Food and Drug Safety on July 30. With this approval, Imfinzi has become the first and only immunotherapy in Korea to be approved for
- Company
- US drug price 3.9 times higher than in Korea
- by Kim, Jin-Gu Aug 6, 2025 06:09am
- With the US government pushing forward the introduction of a Most Favored Nation (MFN) policy to lower drug prices, an analysis has revealed that US drug prices are 3.9 times higher than those in South Korea. The Korea Biotechnology Industry Organization cited an analysis by the US public policy research institute Rand Corporation on the
- Company
- GIST drug Qinlock receives orphan drug designation in KOR
- by Eo, Yun-Ho Aug 6, 2025 06:09am
- The GIST treatment Qinlock has been designated as an orphan drug in Korea. The Ministry of Food and Drug Safety announced the news through a public notice on the 4th. Ono Pharmaceutical's gastrointestinal stromal tumor (GIST) treatment Qinlock (ripreitinib) had previously been designated as a Global Innovative Products on Fast Track (GIFT
- Company
- COVID-19 vaccination system has been included in the NIP
- by Whang, byung-woo Aug 6, 2025 06:09am
- As COVID-19 vaccination has been included in the National Immunization Program (NIP), changes to the operational system is anticipated. Previously, government provided COVID-19 immunization service for high-risk groups. Whereas the previous service had been temporary, the current vaccination system is expected to become more established. T
- Company
- Organon-KSCRH implements Implanon NTX Certificate Program
- by Whang, byung-woo Aug 5, 2025 06:08am
- The Implanon NXT Certificate Program, jointly implemented by Organon Korea and the Korean Society of Contraception and Reproductive Health, is yielding positive results. Organon Korea announced on the 4th that 172 medical professionals have received certification through the ‘Implanon NTX Certificate Program,’ which has been in operatio
- Company
- Generic companies challenge Xtandi’s patent in KOR
- by Kim, Jin-Gu Aug 5, 2025 06:08am
- Astellas' prostate cancer treatment ‘Xtandi (enzalutamide)’ has become the target of a patent challenge by a generic drug company. According to industry sources on the 4th, Alvogen Korea recently filed a request for invalidation trial (passive scope confirmation trial) of the composition patent for Xtandi against Astellas. This is the
- Company
- Inclusion of Prevenar 20 into NIP for children starting Oct
- by Whang, byung-woo Aug 5, 2025 06:08am
- As Prevenar 20 has been confirmed to be included in the National Immunization Program (NIP) in October, a fierce market competition is anticipated. The implementation has been delayed from its initial expected schedule in Q3. However, it is anticipated to shift the market for pneumococcal conjugate vaccines with the emergence of the newest
